effici
deliveri
sirna
specif
cell
popul
vivo
remain
formid
challeng
success
therapeut
applic
describ
novel
sirnabas
approach
synthet
link
sirna
oligonucleotid
agonist
target
silenc
gene
myeloid
cell
b
cell
key
compon
tumor
microenviron
tumorassoci
immun
cell
suppress
antitumor
immun
respons
hinder
immun
stimul
test
conjug
antitumor
effect
inject
local
tumor
site
system
intraven
rout
conjug
access
tumorassoci
dendrit
cell
macrophag
b
cell
inhibit
express
lead
activ
tumorassoci
immun
cell
ultim
potent
antitumor
immun
respons
find
demonstr
potenti
tlr
agonist
sirna
conjug
target
gene
silenc
coupl
tlr
stimul
immun
activ
tumor
microenviron
rna
interfer
provid
compel
opportun
control
gene
express
cell
sirna
therefor
repres
famili
new
drug
broad
potenti
treatment
divers
human
diseas
sever
recent
studi
demonstr
feasibl
vivo
sirna
deliveri
lead
therapeut
effect
mous
model
also
nonhumanprim
nevertheless
effici
vivo
target
deliveri
sirna
specif
cell
type
especi
immun
origin
import
constitu
tumor
microenviron
activ
player
promot
tumor
progress
remain
fulli
explor
one
promis
approach
target
deliveri
sirna
use
aptam
oligonucleotidebas
ligand
bind
specif
receptor
tumor
cell
immun
system
serv
extrins
tumor
suppressor
howev
tumor
microenviron
character
lack
tumorspecif
cell
excess
regulatori
cell
myeloidderiv
suppressor
cell
mdsc
promot
tumor
immun
evas
myeloid
cell
immun
cell
tumor
microenviron
also
produc
growth
factor
angiogenicmetastat
factor
critic
tumor
progress
orchestr
process
tumor
microenviron
appear
highli
depend
oncogen
transcript
factor
particular
other
recent
demonstr
role
mediat
tumor
immun
evas
activ
myeloid
cell
inhibit
express
larg
number
immunostimulatori
molecul
relat
respons
promot
product
sever
key
immunosuppress
factor
well
angiogen
factor
addit
mediat
signal
certain
cytokin
growth
factor
notabl
activ
myeloid
cell
activ
tumor
cell
enhanc
tumor
cell
prolifer
surviv
also
restrain
tlrmediat
immun
respons
reason
simultan
silenc
sirna
trigger
tlr
agonist
could
effect
shift
tumor
microenviron
prooncogen
antitumor
recent
studi
use
polymermedi
vivo
transfect
sirna
demonstr
benefit
simultan
induc
antitumor
immun
silenc
prooncogen
gene
studi
explor
strategi
link
sirna
synthet
oligonucleotid
agonist
endosom
tlr
includ
target
deliveri
sirna
immun
cell
togeth
tlrdepend
activ
antitumor
immun
respons
endosom
locat
oligonucleotidebind
tlr
might
advantag
facilit
sirna
compon
reach
cytosol
effici
gene
silenc
cell
select
express
cognat
tlr
order
model
concept
chose
oligodeoxynucleotid
contain
unmethyl
cpgmotif
cpg
odn
alreadi
clinic
test
addit
cpg
odn
effici
intern
variou
antigenpres
cell
dendrit
cell
dc
macrophag
b
cell
bind
initi
cascad
innat
adapt
immun
respons
myeloid
cell
b
cell
also
critic
compon
tumor
microenviron
activ
promot
oncogenesi
link
singlestrand
cpg
odn
doublestrand
sirna
creat
singl
synthet
molecul
capabl
deliv
sirna
myeloid
b
cell
silenc
immun
checkpoint
andor
oncogen
gene
activ
tlr
lead
therapeut
antitumor
immun
respons
synthesi
antisens
strand
sirna
follow
odn
synthesi
produc
singl
strand
oligonucleotid
connect
carbon
chain
linker
fig
sirna
chosen
convent
duplex
allow
uncoupl
sirna
cpg
sequenc
dicer
enzym
insid
cell
asymmetr
sirna
optim
specif
process
dicer
potent
target
gene
silenc
ad
either
alon
sirna
conjug
cultur
dendrit
cell
result
similar
increas
express
costimulatori
molecul
suggest
sirna
conjug
retain
capac
activ
fig
addit
immunostimulatori
properti
cpgsirna
conjug
differ
effect
cpg
alon
measur
product
inflammatori
cytokin
primari
cell
activ
stabl
macrophag
cell
line
supplementari
fig
assess
whether
link
sirna
cpg
moieti
would
still
allow
dicer
process
compar
vitro
dicer
activ
sirna
substrat
versu
sirna
sirna
sirna
process
sirna
recombin
dicer
fig
final
determin
whether
sirna
retain
gene
silenc
function
chimer
molecul
transfect
cell
use
lipofectamin
result
experi
indic
link
cpg
odn
sirna
interfer
gene
silenc
protein
level
respect
measur
densitometri
fig
determin
specif
effici
cpgsirna
uptak
freshli
prepar
mous
splenocyt
incub
cpglink
sirna
unconjug
sirna
absenc
transfect
reagent
sirna
unconjug
sirna
label
fluorescein
isothiocyan
fitc
fluoresceinposit
dc
macrophag
b
cell
granulocyt
cell
assess
flow
cytometr
analysi
indic
chimer
sirna
effici
taken
plasmacytoid
convent
splenic
dc
macrophag
b
cell
minim
splenic
granulocyt
cell
fig
supplementari
fig
supplementari
tabl
uptak
pattern
reflect
known
distribut
express
murin
leukocyt
subset
intracellular
stain
fix
splenocyt
flow
cytometri
dc
confirm
express
fig
bottom
right
unconjug
sirna
effici
incorpor
dc
even
h
incub
demonstr
linkag
ligand
facilit
sirna
uptak
fig
bottom
left
evalu
sirnafitc
uptak
dc
mous
dc
flow
cytometri
fluoresc
microscopi
indic
without
transfect
reagent
sirnafitc
intern
dc
cell
kinet
similar
cpgodn
alon
fig
two
top
row
supplementari
fig
report
previous
min
greater
dc
cell
posit
uptak
conjug
confirm
confoc
microscop
analysi
uptak
sirnafitc
dose
depend
fig
bottom
row
confoc
microscop
analys
show
one
hour
incub
sirna
coloc
within
perinuclear
endocyt
vesicl
fig
two
top
row
supplementari
fig
coloc
diminish
h
cpgsirna
treatment
fig
two
top
row
previou
studi
demonstr
bind
dicer
nucleas
sirna
oligonucleotid
requir
sirna
process
shorter
fragment
mediat
risc
complexdepend
mrna
degrad
observ
transient
coloc
sirna
dicer
within
h
ad
oligonucleotid
cultur
dc
fig
two
bottom
row
supplementari
fig
coloc
dicer
becam
weaker
h
fig
undetect
h
data
shown
gene
silenc
effect
sirna
cell
determin
quantit
realtim
pcr
analysi
mrna
fig
maximum
effect
silenc
observ
rel
high
concentr
sirna
serumcontain
cell
cultur
medium
gpcconjug
sirna
bind
activ
fail
silenc
suggest
possibl
requir
activ
cpgsirna
process
experi
demonstr
myeloid
cell
dc
cellular
uptak
sirna
normal
supplementari
fig
gene
silenc
effect
cpgsirna
impair
fig
also
confirm
gene
silenc
effect
use
electrophoret
mobil
shift
assay
emsa
detect
dnabind
activ
cell
induc
stimul
fig
note
indic
stimul
use
cpg
also
result
activ
fig
therebi
complic
emsa
analysi
detect
silenc
nonetheless
higher
concentr
sirna
diminish
dnabind
activ
rel
conjug
scrambl
rna
control
demonstr
gener
approach
gene
silenc
use
mous
b
cell
lymphoma
cell
test
cpgsirna
intern
supplementari
fig
gene
silenc
test
chimer
conjug
link
odn
dicer
substrat
sirna
specif
firefli
luciferas
luc
inhibit
luciferas
activ
cell
supplementari
fig
b
biodistribut
experi
naiv
tumorfre
mice
confirm
sirna
specif
intern
resid
macrophag
differ
tissu
well
dc
b
cell
lymph
node
supplementari
fig
also
assess
uptak
sirna
macrophag
dc
tumorbear
mice
mice
tumor
inject
peritumor
sirna
fitc
nmol
inject
immunofluoresc
stain
show
myeloid
cell
posit
sirna
accumul
inject
site
fig
flow
cytometri
also
indic
presenc
sirna
tumorassoci
myeloid
cell
supplementari
fig
furthermor
vivo
intravit
twophoton
microscopi
show
presenc
fitcposit
cell
tumor
drain
lymph
node
tdln
earli
h
inject
label
construct
fig
supplementari
fig
supplementari
fig
contralater
lymph
node
supplementari
fig
addit
high
resolut
imag
intravit
twophoton
microscopi
reveal
increas
number
fitcposit
cell
tdln
well
accumul
fitclabel
sirna
perinuclear
endocyt
vesicl
fig
bottom
right
also
observ
cultur
dc
fig
next
evalu
gene
silenc
antitumor
effect
sirna
vivo
peritumor
inject
sirna
result
rel
effect
gene
silenc
dc
macrophag
b
cell
tdln
compar
control
cpgluc
sirna
measur
quantit
realtim
pcr
fig
inhibit
dc
isol
tdln
confirm
protein
level
fig
furthermor
quantit
realtim
pcr
western
blot
indic
silenc
total
tdln
supplementari
fig
also
use
cpgluc
sirna
conjug
confirm
cpgsirna
conjug
abl
reduc
protein
express
specif
within
myeloid
cell
vivo
mice
overexpress
firefli
luciferas
control
promot
challeng
tumor
cell
follow
repeat
peritumor
inject
cpgluc
sirna
result
experi
indic
effect
inhibit
luciferas
activ
myeloid
cell
lymphocyt
within
tdln
fig
dc
macrophag
tumor
microenviron
known
promot
immun
toler
previou
work
demonstr
persistentlyactiv
myeloid
cell
tumor
milieu
genet
ablat
myeloid
compart
elicit
potent
antitumor
immun
furthermor
cpg
lp
treatment
activ
act
neg
feedback
mechan
constrain
immun
respons
therefor
assess
whether
conjug
could
revers
immunosuppress
effect
impos
tumormicroenviron
time
allow
effect
antitumor
immun
induc
trigger
local
treatment
sirna
oligonucleotid
inhibit
growth
subcutan
grow
melanoma
mm
diamet
initi
treatment
contrast
treatment
unconjug
cpgodn
plu
sirna
cpgscrambl
rna
construct
sirna
significantli
less
antitumor
effect
fig
antitumor
effect
sirna
confirm
use
two
altern
sirna
sequenc
data
shown
directli
show
antitumor
effect
induc
sirna
mainli
mediat
immun
cell
perform
vivo
experi
antibodymedi
deplet
cell
nk
cell
without
immun
cell
popul
possibl
also
crossprim
dc
effect
sirna
treatment
partial
reduc
fig
therapeut
effect
sirna
abrog
absenc
nk
cell
fig
confirm
local
treatment
sirna
reduc
growth
tumor
independ
genet
background
sirna
oligonucleotid
inhibit
growth
poorli
immunogen
variant
melanoma
colon
carcinoma
balbc
mice
respect
fig
furthermor
sirna
treatment
carcinoembryon
antigen
cea
transgen
mice
bear
colon
carcinoma
express
cea
led
tumor
regress
mice
fig
assess
vivo
effect
sirna
tumor
cell
stain
tumor
tissu
fluoresc
antibodi
specif
activ
data
analysi
show
tumor
receiv
sirna
undergon
extens
apoptosi
rel
three
treatment
group
supplementari
fig
also
investig
possibl
sirna
could
system
deliv
achiev
gene
silenc
antitumor
effect
intraven
inject
iv
sirna
nmol
reduc
express
dc
within
tdln
rel
cpgscrambl
rna
fig
system
deliveri
sirna
inhibit
metastasi
test
experiment
lung
metastasi
model
rel
small
amount
oligonucleotid
mgkg
use
system
inject
led
signific
reduct
number
lung
metastasi
fig
lower
antitumor
effect
due
cpgscrambl
rna
cpg
odn
alon
also
observ
thu
maxim
antitumor
effect
requir
conjug
cpg
ligand
function
sirna
assess
role
immun
modul
observ
antitumor
effect
mediat
sirna
conjug
treatment
analyz
chang
cytokin
chemokin
costimulatori
molecul
express
dc
tdln
lack
dc
shown
upregul
express
cytokineschemokin
greatli
amplifi
cpg
treatment
shown
fig
inject
sirna
tumor
site
result
upregul
sever
cytokin
chemokin
shown
upregul
ablat
also
document
dc
low
express
level
costimulatori
molecul
mediat
immun
toler
one
propos
mechan
tumor
immun
evas
induc
activ
tumorassoci
dc
therefor
analyz
express
costimulatori
molecul
dc
enrich
tdln
result
analys
indic
sirna
reduc
number
dc
low
express
costimulatori
molecul
includ
mhc
class
ii
accompani
modest
increas
express
costimulatori
molecul
supplementari
fig
ablat
myeloid
cell
follow
local
treatment
shown
induc
potent
antitumor
innat
immun
respons
involv
neutrophil
therefor
assess
whether
sirna
conjug
treatment
could
lead
neutrophilassoci
tumor
cell
apoptosi
costain
tumor
tissu
section
antibodi
specif
activ
neutrophil
reveal
sirna
treatmentinduc
massiv
tumor
cell
apoptosi
activ
caspas
associ
increas
tumorinfiltr
neutrophil
fig
increas
neutrophil
tumor
sirna
treatment
confirm
flow
cytometri
fig
ratio
effector
regulatori
cell
within
tumor
microenviron
consid
indic
effect
adapt
immun
respons
tumor
progress
metastasi
investig
number
tumor
infiltr
cell
popul
subcutan
grow
tumor
treat
local
week
sirna
cpgscrambl
rna
control
pb
although
sirna
treatment
induc
signific
chang
overal
cell
number
within
tumor
shown
flow
cytometr
analysi
fig
percentag
treg
cell
within
cell
drop
approxim
peritumor
inject
sirna
fig
observ
increas
infiltr
total
cell
tumor
stroma
although
cpgscrambl
rna
control
treatment
also
led
recruit
cell
fig
effect
probabl
result
immunostimul
tumorinfiltr
antigen
present
cell
fluoresc
immunostain
frozen
tumor
tissu
antibodi
confirm
data
gener
flow
cytometr
analysi
sirna
treatment
caus
increas
cell
infiltr
tumor
data
shown
activ
tumor
antigenspecif
cell
believ
critic
immunemedi
antitumor
effect
therefor
examin
abil
sirna
treatment
gener
cell
specif
tumor
antigen
elispot
assay
determin
product
cell
isol
tdln
respons
recal
stimul
peptid
antigen
indic
vivo
sirna
administr
inde
induc
antigenspecif
cell
fig
develop
new
strategi
target
sirna
deliveri
togeth
immun
activ
coval
link
tlr
oligonucleotid
agonist
sirna
conjug
encompass
three
activ
singl
molecul
target
immun
cell
includ
dc
macrophag
b
cell
tlr
activ
immun
checkpoint
silenc
addit
sever
intracellular
tlr
also
recognizeinteract
nucleic
acid
suggest
broad
applic
approach
use
variou
ligand
tlr
deliv
sirna
differ
immun
cell
tlr
import
stimul
dc
matur
antigen
uptak
present
lead
ctl
activ
helper
cell
differenti
therefor
tlr
agonistsirna
approach
stimul
desir
immun
respons
treat
diseas
cancer
infect
although
establish
bind
necessari
cpgmediat
immun
activ
remain
fulli
explor
cpg
odn
enter
cell
result
indic
cellular
uptak
cpg
odn
cpgsirna
construct
occur
absenc
howev
least
mous
cell
essenti
cpgsirnamedi
gene
silenc
exact
underli
mechan
remain
determin
possibl
trigger
could
effect
either
endosom
releas
cpgsirna
cytoplasm
orand
intracellular
process
although
express
differ
type
mous
dc
express
select
human
nevertheless
highest
level
constitut
express
observ
human
plasmacytoid
dc
b
cell
also
express
lower
level
human
monocyt
macrophag
immun
cell
serv
antigenpres
cell
induc
innat
adapt
humor
immun
furthermor
demonstr
recent
ad
triphosph
sirna
potenti
antitumor
effect
sirna
stimul
antitumor
immun
respons
like
intracellular
rna
sensor
rigi
therefor
conceiv
incorpor
triphosph
cpgsirna
amplifi
antitumor
immun
addit
critic
role
tumor
stromal
macrophag
b
cell
promot
tumor
develop
well
document
importantli
sever
molecul
produc
tumor
myeloid
popul
possibl
tumorassoci
b
cell
critic
tumor
immunosuppress
activ
myeloid
compart
possibl
b
cell
well
promot
activ
tumor
cell
endotheli
cell
tumor
enhanc
tumor
cell
growthsurviv
addit
oncogen
molecul
produc
tumor
myeloidb
cell
compart
also
critic
promot
cancer
growth
resist
variou
therapi
therefor
abl
target
tumor
stromal
myeloid
cellsb
cell
cpgsirna
conjug
molecul
highli
desir
cancer
therapi
addit
normal
immun
cell
sever
type
tumor
cell
includ
b
cell
origin
solid
tumor
cell
also
posit
preliminari
result
suggest
feasibl
cpgsirna
approach
silenc
gene
tumor
cell
exampl
treat
human
tumor
mice
sirna
result
tumor
cell
apoptosi
tumor
growth
inhibit
kortylewski
yu
unpublish
data
experi
remain
perform
optim
approach
potenti
clinic
use
result
indic
gene
silenc
effect
cpgsirna
cultur
cell
requir
high
concentr
conjug
suboptim
rel
vivo
treatment
work
underway
determin
possibl
caus
differ
might
includ
serumassoci
degrad
cpgsirna
reduct
overal
silenc
effect
rapidli
divid
cell
popul
possibl
vivo
repeat
treatment
allow
accumul
gene
silenc
effect
crosstalk
variou
cell
tumor
microenviron
could
lead
secondari
inhibitori
effect
activ
halflif
construct
present
limit
although
cpg
odn
construct
phosphothio
resist
serum
degrad
sirna
chimer
construct
unmodifi
neg
charg
chemic
modifi
sirna
prolong
serum
stabil
neutral
neg
charg
sirna
facilit
endosom
releas
may
improv
efficaci
tlr
agonistsirna
approach
although
studi
necessari
understand
mechan
improv
cpgsirna
gene
silenc
effect
result
rais
possibl
use
oligonucleotid
tlr
agonist
sirna
deliveri
tumorassoci
myeloid
cell
b
cell
possibl
certain
tumor
cell
inhibit
express
tumorpromotingimmunosuppress
molecul
activ
tlr
immun
activ
murin
melanoma
colon
carcinoma
b
cell
lymphoma
line
purchas
american
type
cultur
collect
mous
dendrit
cell
origin
dr
kenneth
rock
univers
massachusett
medic
school
highli
metastat
clone
melanoma
kindli
provid
dr
huang
j
fidler
anderson
cancer
center
houston
tx
stabli
transduc
cell
line
provid
dr
defu
zheng
citi
hope
duart
ca
gener
transgen
mice
cell
line
previous
describ
phosphothio
oligodeoxyribonucleotid
odn
antisens
strand
sirna
link
use
unit
carbon
chain
linker
ch
sequenc
firefli
luciferasespecif
sirna
r
use
sirna
conjug
molecul
publish
correct
format
sirna
duplex
confirm
vitro
dicer
cleavag
assay
odnsirna
construct
subject
process
dicer
ambion
h
resolv
urea
gel
result
dice
reaction
visual
sybr
gold
stain
invitrogen
total
rna
extract
cultur
primari
cell
use
rneasi
kit
qiagen
cdna
synthesi
use
iscript
cdna
synthesi
kit
biorad
sampl
analyz
use
pair
primer
specif
tnf
rant
gapdh
mrna
superarray
bioscienc
corpor
sequencespecif
amplif
detect
fluoresc
signal
sybr
green
biorad
use
realtim
pcr
detector
biorad
cell
transient
transfect
nm
cpglink
uncoupl
sirna
scrambl
rna
use
lipofectamin
invitrogen
h
later
cell
lyse
use
western
blot
analysi
emsa
western
blot
analysi
detect
dnabind
protein
express
perform
describ
previous
protein
level
detect
western
blot
later
quantifi
densitometri
use
alphaeas
fc
softwar
alpha
innotech
luc
mice
treat
cpgluc
sirna
lyse
luciferas
activ
determin
use
luciferas
assay
system
promega
normal
protein
content
sampl
mous
care
experiment
procedur
perform
pathogenfre
condit
accord
establish
institut
guidanc
approv
protocol
research
anim
care
committe
citi
hope
sc
tumor
challeng
inject
tumor
cell
week
balbc
mice
respect
tumor
reach
averag
size
ca
mm
mice
inject
peritumor
nmol
odn
alon
combin
sirna
cpggpc
odn
link
variou
doubl
strand
rna
dsrna
sequenc
describ
tumor
growth
monitor
everi
day
analysi
cellular
molecular
mechan
cpggpcdsrna
effect
mice
kill
week
treatment
experi
silenc
luciferas
activ
vivo
luc
mice
origin
kindli
provid
dr
christoph
h
contag
stanford
univers
school
medicin
ca
challeng
tumor
treat
daili
inject
cpgluc
sirna
cpgscrambl
rna
lymph
node
well
tumor
specimen
harvest
lung
metastasi
model
mice
challeng
tumor
cell
iv
two
later
tumor
establish
treat
system
nmol
ca
mgkg
odn
variou
cpgdsrna
intraven
inject
repeat
everi
day
two
week
lung
harvest
fix
number
tumor
coloni
manual
count
level
silenc
assess
realtim
pcr
dc
isol
tumordrain
inguin
sc
tumor
model
cervic
metastasi
model
lymph
node
immun
cell
deplet
mice
pretreat
plu
antibodi
clone
respect
deplet
cell
respect
antibodi
wako
deplet
min
nk
cell
tumor
inocul
inject
weekli
prepar
singlecel
suspens
spleen
lymph
node
tumor
tissu
mechan
dispers
follow
collagenas
ddnase
treatment
describ
extracellular
stain
immun
marker
freshli
prepar
cell
suspend
wv
sodium
azid
preincub
antibodi
block
nonspecif
bind
stain
differ
combin
fluorochromecoupl
antibodi
ia
b
mhcii
bd
bioscienc
prior
intracellular
stain
antibodi
ebiosci
dicer
santa
cruz
ebiosci
variou
immun
cell
subset
fix
paraformaldehyd
permeat
methanol
fluoresc
data
collect
facscalibur
beckton
dickinson
analyz
use
flowjo
softwar
tree
star
elispot
assay
cell
isol
form
tdln
cpgor
cpgsirnastr
mice
seed
well
filtrat
plate
presenc
absenc
peptid
h
incub
peptidespecif
spot
detect
accord
manufactur
procedur
cell
scienc
scan
quantifi
use
immunospot
analyz
cellular
technolog
ltd
immunofluoresc
stain
fix
flashfrozen
tumor
specimen
formaldehyd
permeabil
methanol
antibodi
stain
confoc
microscopi
cultur
cell
fix
paraformadehyd
permeabil
triton
mm
mgcl
mm
cacl
quench
mm
nh
cl
block
bsa
h
sampl
stain
antibodi
bd
bioscienc
neutrophil
cedarlan
activ
cell
signal
ebiosci
dicer
santa
cruz
detect
secondari
antibodi
invitrogen
stain
nuclei
dapi
vector
hoechst
slide
mount
analyz
fluoresc
confoc
microscopi
confoc
imag
carri
use
water
immers
object
confoc
microscop
zeiss
intravit
twophoton
imag
tumorbear
mice
receiv
singl
intratumor
inject
nmol
fitclabel
sirna
follow
retroorbit
inject
dextranrhodamin
invitrogen
hoechst
prior
imag
h
later
mice
anesthet
intravit
twophoton
microscopi
carri
use
equip
softwar
ultima
multiphoton
microscopi
system
unpair
ttest
equal
unequ
varianc
specif
analysi
cytokin
express
fig
use
calcul
twotail
p
valu
estim
statist
signific
differ
two
treatment
group
whole
studi
oneway
anova
follow
newmankeul
test
appli
comparison
multipl
treatment
group
twoway
anova
plu
bonferroni
posttest
appli
assess
statist
signific
differ
tumor
growth
kinet
multipl
treatment
group
statist
signific
p
valu
indic
figur
andor
legend
label
cell
n
statist
signific
differ
sirnaand
cpgscrambl
rnatreat
group
indic
asterisk
similar
result
obtain
independ
experi
b
tumor
growth
inhibit
sirna
involv
nk
celland
cellmedi
immun
mice
establish
tumor
deplet
nk
cell
lymphocyt
prior
sirna
treatment
shown
mean
sem
p
twoway
anova
test
c
local
treatment
sirna
reduc
growth
melanoma
c
colon
carcinoma
tumor
cell
inject
sc
balbc
mice
respect
mice
establish
tumor
treat
peritumor
inject
sirna
cpgluc
sirna
cpg
alon
pb
everi
day
start
challeng
tumor
cell
statist
signific
differ
cpgsirnatr
group
indic
asterisk
e
mice
challeng
sc
cell
treat
describ
use
sirna
cpgluc
sirna
start
tumor
challeng
p
twoway
anova
n
group
f
system
treatment
sirna
reduc
express
dc
within
tdln
cervic
sampl
pool
micegroup
analyz
realtim
pcr
shown
averag
level
express
sirnatr
mice
one
two
independ
experi
analyz
triplic
sem
rel
control
cpgscrambl
rna
set
